JP2005529082A - ９−デオキソ−９ａ−アザ−９ａ−メチル−９ａ−ホモエリスロマイシンＡ等構造擬似多形 - Google Patents

９−デオキソ−９ａ−アザ−９ａ−メチル−９ａ−ホモエリスロマイシンＡ等構造擬似多形 Download PDF

Info

Publication number
JP2005529082A
JP2005529082A JP2003575884A JP2003575884A JP2005529082A JP 2005529082 A JP2005529082 A JP 2005529082A JP 2003575884 A JP2003575884 A JP 2003575884A JP 2003575884 A JP2003575884 A JP 2003575884A JP 2005529082 A JP2005529082 A JP 2005529082A
Authority
JP
Japan
Prior art keywords
deoxo
aza
homoerythromycin
methyl
pseudopolymorph
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2003575884A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005529082A5 (2
Inventor
デュミック，ミリエンコ
ヴィンコヴィッチ，ムラデン
オレシック，マリナ
メストロヴィッチ，エルネスト
ダニロフスキー，アレクサンダー
ダムボヴィッチ，アロイズ
クネツェヴィッチ，ズドラフカ
ラザレフスキー，ゴリアナ
シンシック，ドミニク
フィリック，ダルコ
ラザリック，カティカ
ブカール，デヤン−クレシミール
Original Assignee
プリバ−イストラジヴァッキ・インスティテュート・ディーオーオー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by プリバ−イストラジヴァッキ・インスティテュート・ディーオーオー filed Critical プリバ−イストラジヴァッキ・インスティテュート・ディーオーオー
Publication of JP2005529082A publication Critical patent/JP2005529082A/ja
Publication of JP2005529082A5 publication Critical patent/JP2005529082A5/ja
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Thermal Transfer Or Thermal Recording In General (AREA)
  • Non-Silver Salt Photosensitive Materials And Non-Silver Salt Photography (AREA)
  • Finger-Pressure Massage (AREA)
  • Instructional Devices (AREA)
JP2003575884A 2002-03-18 2003-03-18 ９−デオキソ−９ａ−アザ−９ａ−メチル−９ａ−ホモエリスロマイシンＡ等構造擬似多形 Abandoned JP2005529082A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
HR20020231A HRP20020231A2 (en) 2002-03-18 2002-03-18 ISOSTRUCTURAL PSEUDOPOLYMORPHS OF 9-DEOXO-9a-AZA-9a-METHYL-9a-HOMOERYTHROMYCIN A
US39361202P 2002-07-03 2002-07-03
US39470502P 2002-07-08 2002-07-08
PCT/IB2003/000987 WO2003077830A2 (en) 2002-03-18 2003-03-18 9-dexo-9a-aza-9a-methyl-9a-homoerythromycin a derivatives

Publications (2)

Publication Number Publication Date
JP2005529082A true JP2005529082A (ja) 2005-09-29
JP2005529082A5 JP2005529082A5 (2) 2006-04-06

Family

ID=28045976

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003575884A Abandoned JP2005529082A (ja) 2002-03-18 2003-03-18 ９−デオキソ−９ａ−アザ−９ａ−メチル−９ａ−ホモエリスロマイシンＡ等構造擬似多形

Country Status (23)

Country Link
US (1) US7569549B2 (2)
EP (2) EP1485393B1 (2)
JP (1) JP2005529082A (2)
KR (1) KR20050002872A (2)
CN (1) CN1642966A (2)
AT (1) ATE440104T1 (2)
AU (1) AU2003215779A1 (2)
BG (1) BG108874A (2)
BR (1) BR0308644A (2)
CA (1) CA2479211A1 (2)
DE (1) DE60328872D1 (2)
EA (1) EA200401217A1 (2)
ES (1) ES2331733T3 (2)
HR (2) HRP20020231A2 (2)
IL (1) IL163836A0 (2)
IS (1) IS7449A (2)
MX (1) MXPA04009009A (2)
NO (1) NO20044341L (2)
NZ (1) NZ535477A (2)
PL (1) PL372468A1 (2)
RS (1) RS82504A (2)
TN (1) TNSN04166A1 (2)
WO (1) WO2003077830A2 (2)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20020231A2 (en) 2002-03-18 2003-12-31 Pliva D D ISOSTRUCTURAL PSEUDOPOLYMORPHS OF 9-DEOXO-9a-AZA-9a-METHYL-9a-HOMOERYTHROMYCIN A
HRP20020614A2 (en) * 2002-07-22 2004-06-30 PLIVA-ISTRAŽIVAČKI INSTITUT d.o.o. Rhombic pseudopolymorph of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin a
ATE421882T1 (de) * 2003-07-24 2009-02-15 Pliva Hrvatska D O O Schnellösliches azithromycin in einzeldosisform
EP1878432A1 (en) * 2003-07-24 2008-01-16 Pliva - Research and Development Ltd. Single dose fast dissolving azithromycin
ES2600577T3 (es) * 2003-12-04 2017-02-09 Bend Research, Inc. Procedimiento de pulverización-solidificación que usa un extrusor para preparar composiciones en multipartículas de fármacos cristalinos
US6984403B2 (en) * 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
KR100844628B1 (ko) * 2003-12-04 2008-07-07 화이자 프로덕츠 인크. 제약상 다입자의 제조 방법
WO2005053652A1 (en) 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride
MXPA06005913A (es) * 2003-12-04 2006-06-27 Pfizer Prod Inc Formas de dosificacion de multiparticulas de azitromicina por procedimientos basados en liquidos.
CA2547597A1 (en) 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate compositions with improved stability
US20060116336A1 (en) * 2004-03-17 2006-06-01 American Pharmaceutical Partners, Inc. Lyophilized azithromycin formulation
US7468428B2 (en) * 2004-03-17 2008-12-23 App Pharmaceuticals, Llc Lyophilized azithromycin formulation

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI8110592A8 (en) * 1981-03-06 1996-06-30 Pliva Pharm & Chem Works Process for preparing of n-methyl-11-aza-10-deoxo-10-dihydroerythromycine a and derivatives thereof
WO1989000576A1 (en) * 1987-07-09 1989-01-26 Pfizer Inc. Azithromycin dihydrate
HRP20020231A2 (en) 2002-03-18 2003-12-31 Pliva D D ISOSTRUCTURAL PSEUDOPOLYMORPHS OF 9-DEOXO-9a-AZA-9a-METHYL-9a-HOMOERYTHROMYCIN A
US5686587A (en) 1993-05-19 1997-11-11 Pfizer Inc. Intermediate for azithromycin
HRP940251B1 (en) 1994-04-15 1998-12-31 Stjepan Mutak Process for the preparation of azithromycin dihydrochloride
ES2122905B1 (es) * 1996-07-11 1999-11-16 Astur Pharma Sa Sintesis de 11,12-hidrogenoortoborato de 9-desoxo-9a-aza-11,12-desoxi-9a-metil-9a-homoeritromicina a. un procedimiento para la preparacion de 9-desoxo-9a-aza-9a-metil-9a-homoeritromicina a dihidrato (azitromicina dihidrato).
PT102130A (pt) 1998-03-13 1999-09-30 Hovione Sociedade Quimica S A Processo de preparacao de dihidrato de azitromicina
CN1205338A (zh) 1998-05-08 1999-01-20 刘万忠 阿奇霉素水溶性盐的合成新方法及其在医药上的用途
TW546302B (en) * 1998-05-08 2003-08-11 Biochemie Sa Improvements in macrolide production
CA2245398C (en) 1998-08-21 2002-01-29 Apotex Inc. Azithromycin monohydrate isopropanol clathrate and methods for the manufacture thereof
SI20639A (sl) * 1998-11-30 2002-02-28 Teva Pharmaceutical Industries Ltd. Etanolat azitromicina, postopek za njegovo pripravo in njegovi farmacevtski sestavki
AU5820400A (en) * 1999-06-29 2001-01-31 Biochemie S.A. Macrolides
ES2177373B1 (es) * 1999-11-26 2003-11-01 Astur Pharma Sa Preparacion de azitromicina en su forma no cristalina
EP1246831B1 (en) * 2000-01-04 2008-03-05 Teva Pharmaceutical Industries Ltd. Preparation method of azithromycin dihydrate
ES2162764B1 (es) * 2000-05-17 2003-04-01 Ercros Ind Sa Forma polimorfica del dihidrato de azitromicina, y su procedimiento deobtencion.
DE60026718T2 (de) * 2000-07-25 2006-11-16 Laboratorio Silanes, S.A. De C.V. Einstufiges verfahren zur herstellung von 7,16-deoxy-2-aza-10-o-cladinosil-12-o-desosaminil-4,5-dihydroxi-6-ethyl-3,5,9,11,13,15-hexamethylbicycle(11.2.11)hexadeca-1(2)-en-8-ona undeine neue form von 9-desoxo-9a-methyl-9a-aza-9a-homoerythromycin a
JP2004506664A (ja) * 2000-08-23 2004-03-04 ウォックハート・リミテッド 無水アジトロマイシンの製造法
HRP20030430B1 (hr) 2000-11-27 2011-11-30 Biochemie S.A. Makrolidni solvati
KR100491183B1 (ko) 2001-03-21 2005-05-25 한미약품 주식회사 아지트로마이신의 제조방법 및 이 방법에 사용되는9-데옥소-9에이-아자-9에이-호모에리트로마이신 에이의결정성 수화물
KR100431431B1 (ko) 2001-04-25 2004-05-14 한미약품 주식회사 아지트로마이신 수화물의 1,2-프로필렌글리콜 내포화합물,그의 제조방법 및 그의 약학적 조성물
HRP20010301A2 (en) 2001-04-27 2001-12-31 Pliva D D New therapeutic indication for azithromycin in the treatment of non-infective inflammatory diseases
US6861413B2 (en) * 2001-05-22 2005-03-01 Pfizer Inc. Stable non-dihydrate azithromycin oral suspensions
ES2258142T3 (es) * 2001-05-22 2006-08-16 Pfizer Products Inc. Nueva forma cristalina.
PL371259A1 (pl) * 2001-12-21 2005-06-13 Pfizer Products Inc. Bezpośrednio sprasowywalne preparaty azytromycyny
NZ532063A (en) * 2001-12-21 2006-03-31 Pfizer Prod Inc Methods for wet granulating azithromycin
RU2283092C2 (ru) 2002-02-01 2006-09-10 Пфайзер Продактс Инк. Сухие гранулированные композиции азитромицина
ITMI20021209A1 (it) 2002-06-04 2003-12-04 Chemi Spa Processo di preparazione di azitromicina ad elevata purezza

Also Published As

Publication number Publication date
TNSN04166A1 (en) 2007-03-12
BG108874A (en) 2005-12-30
EP1485393A2 (en) 2004-12-15
IS7449A (is) 2004-09-16
WO2003077830A2 (en) 2003-09-25
ATE440104T1 (de) 2009-09-15
HRP20040858A2 (en) 2005-06-30
CA2479211A1 (en) 2003-09-25
US20040014951A1 (en) 2004-01-22
KR20050002872A (ko) 2005-01-10
BR0308644A (pt) 2005-01-25
WO2003077830A3 (en) 2004-05-13
NZ535477A (en) 2006-11-30
EP1627883A1 (en) 2006-02-22
EA200401217A1 (ru) 2005-02-24
NO20044341L (no) 2004-11-23
DE60328872D1 (en) 2009-10-01
AU2003215779A1 (en) 2003-09-29
HRP20020231A2 (en) 2003-12-31
RS82504A (sr) 2006-12-15
PL372468A1 (en) 2005-07-25
US7569549B2 (en) 2009-08-04
CN1642966A (zh) 2005-07-20
IL163836A0 (en) 2005-12-18
ES2331733T3 (es) 2010-01-14
EP1485393B1 (en) 2009-08-19
MXPA04009009A (es) 2005-06-17

Similar Documents

Publication Publication Date Title
CN101573350B (zh) 甲磺酸伊马替尼的多晶型及其制备方法以及无定形和α型的甲磺酸伊马替尼
EP2181117B1 (en) Macrolide solid-state forms
JP2026047356A (ja) ベルモスジル及びベルモスジル塩の固体形態
CN112142679B (zh) 一种吉非替尼与香草酸共晶甲醇溶剂合物及其制备方法
JP2005529082A (ja) ９−デオキソ−９ａ−アザ−９ａ−メチル−９ａ−ホモエリスロマイシンＡ等構造擬似多形
CN105189513A (zh) 葡萄糖醇，1-脱氧-1-(甲胺基)-,1-(6-氨基-3,5-二氟吡啶-2-基)-8-氯-6-氟-1,4-二氢-7-(3-羟基氮杂环丁烷-l-基)-4-氧-3-喹啉羧酸盐的结晶形态
JP5405114B2 (ja) 抗生物質である結晶フシジン酸の調製
US6936591B2 (en) Amorphous 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A, process for preparing the same, and uses thereof
EP4509508A1 (en) Free-state plx5622 crystal form and preparation method therefor
CN112538123B (zh) 一种舒更葡糖钠晶型m
JP2013184902A (ja) リファキシミン含有結晶
EP2882435B1 (en) Pharmaceutical formulations containing 3-(4-cinnamyl-L-piperazinyl) amino derivatives of 3-formylrifamycin S
US20060154953A1 (en) Amorphous tacrolimus and preparation thereof
CN100427499C (zh) 一种阿奇霉素的可溶性盐及其制备方法
WO2021216628A1 (en) Solid state forms of trifarotene and process for preparation thereof
WO2017015784A1 (zh) 奥比特嗪-富马酸盐、水合物、晶型及其制备方法
KR20160146428A (ko) 솔리페나신 또는 그의 약학적으로 허용되는 염과 락토즈를 포함하는 안정한 무정형 솔리페나신 약학 조성물 및 그의 제조방법
ZA200406971B (en) 9-dexo-9a-aza-9a-methyl-9a-homoerythromycin a derivatives.
JP4583601B2 (ja) 新規の６−デオキシエリスロマイシン誘導体、それらの製造方法及びそれらの薬剤としての使用
DE20321227U1 (de) Isostrukturelle Pseudopolymorphe von 9-Deoxo-9a-Aza-9a-Methyl-9a-Homoerythromycin A
WO2022229761A1 (en) SOLID FORM OF 2-CHLORO-2'-DEOXY-ADENOSINE COMPLEX WITH HPβCD
CN121930247A (zh) 苯并噁嗪噁唑烷酮类化合物otb-658的晶型ii及其制备方法和其组合物与用途
JP2008523016A (ja) （５−アミノ−６−メトキシ−３−ピリジンカルボニル）カルバミン酸２−（ｓ）−ヒドロキシムチリン１４−エステルの新規の多形
HK1247726B (zh) 烟酰胺核苷的结晶形式
HK1187351B (en) Optimized synthesis of pure, non-polymorphic, crystalline bile acids with defined particle size

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20060112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20060112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060217

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060217

A762 Written abandonment of application

Free format text: JAPANESE INTERMEDIATE CODE: A762

Effective date: 20060928